Genetic and pharmacologic evidence that mTOR targeting outweighs mTORC1 Inhibition as an antimyeloma strategy

Molecular Cancer Therapeutics

Volumn 13, Issue 2, 2014, Pages 504-516

  Chen, Xi ^a   Díaz Rodríguez, Elena ^a   Ocio, Enrique M ^b   Paiva, Bruno ^b   Mortensen, Deborah S ^c   Lopez Girona, Antonia ^d   Chopra, Rajesh ^d   Miguel, Jesus San ^b   Pandiella, Atanasio ^a  

^a Salamanca Spain   (Spain)

^b HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^c Departments of Medicinal Chemistry   (United States)

^d Translational Development Department   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6-(4-(1H-1,2,4-TRIAZOL-3-YL)PHENYL)-1-(2-(TETRAHYDRO-2H-PYRAN-4-YL)ETHYL)-1H-IMIDAZO(4,5-B)PYRAZIN-2(3H)-ONE; ANTINEOPLASTIC ANTIBIOTIC; IMIDAZOLE DERIVATIVE; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MTOR PROTEIN, HUMAN; MULTIPROTEIN COMPLEX; PYRAZINE DERIVATIVE; RAPAMYCIN; TARGET OF RAPAMYCIN KINASE; TOR COMPLEX 2;

ANTAGONISTS AND INHIBITORS; APOPTOSIS; CELL CYCLE CHECKPOINT; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; COCULTURE; DOSE RESPONSE; DRUG EFFECTS; GENETICS; HEK293 CELL LINE; HUMAN; METABOLISM; MULTIPLE MYELOMA; RNA INTERFERENCE; SIGNAL TRANSDUCTION; STROMA CELL; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE CHECKPOINTS; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; COCULTURE TECHNIQUES; DOSE-RESPONSE RELATIONSHIP, DRUG; HEK293 CELLS; HUMANS; IMIDAZOLES; MULTIPLE MYELOMA; MULTIPROTEIN COMPLEXES; PYRAZINES; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SIROLIMUS; STROMAL CELLS; TOR SERINE-THREONINE KINASES; TUMOR CELLS, CULTURED;

EID: 84894192749     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0022     Document Type: Article

References (50)

1. Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC. Multiple myeloma. Lancet 2009;374:324-39
2. Kyle RA, Rajkumar SV. Multiple myeloma. Blood 2008;111:2962-72
3. Sirohi B, Powles R. Multiple myeloma. Lancet 2004;363:875-87
4. Barlogie B, Shaughnessy J, Tricot G, Jacobson J, Zangari M, Anaissie E, et al. Treatment of multiple myeloma. Blood 2004;103:20-32
5. Mahindra A, Laubach J, Raje N, Munshi N, Richardson PG, Anderson K. Latest advances and current challenges in the treatment of multiple myeloma. Nat Rev Clin Oncol 2012;9:135-43
6. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell 2012;149:274-93
7. Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 2011;12:21-35
8. Hay N, Sonenberg N. Upstream and downstream ofmTOR. Genes Dev 2004;18:1926-45
9. Ma XM, Blenis J. Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol 2009;10:307-18
10. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005; 307:1098-101
11. Hsu J, Shi Y, Krajewski S, Renner S, Fisher M, Reed JC, et al. The AKT kinase is activated in multiple myeloma tumor cells. Blood 2001;98: 2853-5
12. Peterson TR, Laplante M, Thoreen CC, Sancak Y, Kang SA, Kuehl WM, et al. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell 2009; 137:873-86
13. Dowling RJ, Topisirovic I, Fonseca BD, Sonenberg N. Dissecting the role of mTOR: lessons from mTOR inhibitors. Biochim Biophys Acta 2010;1804:433-9
14. Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 2006;5:671-88
15. Benjamin D, Colombi M, Moroni C, Hall MN. Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat Rev Drug Discov 2012;10:868-80
16. KimDH, Sarbassov DD, Ali SM, King JE, Latek RR, Erdjument-Bromage H, et al.mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 2002;110:163-75
17. Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006;22:159-68
18. Montero JC, Chen X, Ocana A, Pandiella A. Predominance ofmTORC1 over mTORC2 in the regulation of proliferation of ovarian cancer cells: therapeutic implications. Mol Cancer Ther 2012;11:1342-52
19. Hsu PP, Kang SA, Rameseder J, Zhang Y, Ottina KA, Lim D, et al. The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1- mediated inhibition of growth factor signaling. Science 2011;332: 1317-22
20. Shah OJ, Wang Z, Hunter T. Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr Biol 2004;14:1650-6
21. Chiang GG, Abraham RT. Targeting the mTOR signaling network in cancer. Trends Mol Med 2007;13:433-42
22. Apsel B, Blair JA, Gonzalez B, Nazif TM, Feldman ME, Aizenstein B, et al. Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol 2008;4: 691-9
23. Carayol N, Vakana E, Sassano A, Kaur S, Goussetis DJ, Glaser H, et al. Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells. Proc Natl Acad Sci U S A 2010;107:12469-74
24. Chresta CM, Davies BR, Hickson I, Harding T, Cosulich S, Critchlow SE, et al. AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res 2010;70: 288-98
25. Montero JC, Seoane S, Ocana A, Pandiella A. P-Rex1 participates in Neuregulin-ErbB signal transduction and its expression correlates with patient outcome in breast cancer. Oncogene 2011;30:1059-71
26. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009; 23:3-9
27. Diaz-Rodriguez E, Alvarez-Fernandez S, Chen X, Paiva B, Lopez-Perez R, Garcia-Hernandez JL, et al. Deficient spindle assembly checkpoint in multiple myeloma. PLoS ONE 2011;6:e27583
28. Carvajal-Vergara X, Tabera S, Montero JC, Esparis-Ogando A, Lopez- Perez R, Mateo G, et al. Multifunctional role of Erk5 in multiple myeloma. Blood 2005;105:4492-9
29. Chow S, Hedley D, Grom P, Magari R, Jacobberger JW, Shankey TV. Whole blood fixation and permeabilization protocol with red blood cell lysis for flow cytometry of intracellular phosphorylated epitopes in leukocyte subpopulations. Cytometry A 2005;67:4-17
30. Ceballos-Cancino G, Espinosa M, Maldonado V, Melendez-Zajgla J. Regulation of mitochondrial Smac/DIABLO-selective release by survivin. Oncogene 2007;26:7569-75
31. Miller CP, Ban K, Dujka ME, McConkey DJ, Munsell M, Palladino M, et al. NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells. Blood 2007;110:267-77
32. Ocio EM, Maiso P, Chen X, Garayoa M, Alvarez-Fernandez S, San- Segundo L, et al. Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks. Blood 2009;113: 3781-91
33. Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, Chng WJ, et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 2007;12:131-44
34. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004;5:R80
35. Pena-Llopis S, Vega-Rubin-de-Celis S, Schwartz JC, Wolff NC, Tran TA, Zou L, et al. Regulation of TFEB and V-ATPases by mTORC1. EMBO J 2011;30:3242-58
36. Yu Y, Yoon SO, Poulogiannis G, Yang Q, Ma XM, Villen J, et al. Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Science 2011;332: 1322-6
37. Mortensen DS, Sapienza J, Lee BG, Perrin-Ninkovic SM, Harris R, Shevlin G, et al. Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. Bioorg Med Chem Lett 2013;23:1588-91
38. Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 2007;7:585-98
39. Stromberg T, Dimberg A, Hammarberg A, Carlson K, Osterborg A, Nilsson K, et al. Rapamycin sensitizes multiple myeloma cells to apoptosis induced by dexamethasone. Blood 2004;103:3138-47
40. Robillard N, Pellat-Deceunynck C, Bataille R. Phenotypic characterization of the human myeloma cell growth fraction. Blood 2005; 105:4845-8
41. Adams JM. Ways of dying: multiple pathways to apoptosis. Genes Dev 2003;17:2481-95
42. Kroemer G, Martin SJ. Caspase-independent cell death. Nat Med 2005;11:725-30
43. Jiang BH, Liu LZ. Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment. Drug Resist Updat 2008; 11:63-76
44. Dubrovska A, Kim S, Salamone RJ, Walker JR, Maira SM, Garcia- Echeverria C, et al. The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc Natl Acad Sci U S A 2009;106:268-73
45. Paino T, Ocio EM, Paiva B, San-Segundo L, Garayoa M, Gutierrez NC, et al. CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype. Haematologica 2012;97:1110-4
46. Maiso P, Liu Y, Morgan B, Azab AK, Ren P, Martin MB, et al. Defining the role of TORC1/2 in multiple myeloma. Blood 2011;118: 6860-70
47. Montero JC, Esparis-Ogando A, Re-Louhau MF, Seoane S, Abad M, Calero R, et al. Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer. Oncogene 2012 Dec 17. [Epub ahead of print].
48. Thoreen CC, Kang SA, Chang JW, Liu Q, Zhang J, Gao Y, et al. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem 2009;284: 8023-32
49. Harbour JW, Luo RX, Dei Santi A, Postigo AA, Dean DC. Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell 1999; 98:859-69
50. Polyak K, Lee MH, Erdjument-Bromage H, Koff A, Roberts JM, Tempst P, et al. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 1994; 78:59-66.